Related Experiment Videos
Dexamethasone augmentation in treatment-resistant depression
T G Dinan1, E Lavelle, J Cooney
1Department of Psychological Medicine, St Bartholomew's Hospital, London, UK.
Acta Psychiatrica Scandinavica
|January 1, 1997
Summary
This study investigated dexamethasone
Area of Science:
- Neuroscience
- Psychiatry
- Endocrinology
Background:
- Major depression is a prevalent mood disorder.
- Treatment resistance is common in major depression.
- The hypothalamic-pituitary-adrenal (HPA) axis is implicated in depression.
Purpose of the Study:
- To assess the efficacy of dexamethasone in treatment-resistant major depression.
- To explore the relationship between baseline cortisol levels and treatment response.
Main Methods:
- Ten patients with treatment-resistant major depression were enrolled.
- Patients received a 4-day course of dexamethasone (3 mg daily) alongside existing antidepressants.
- Serum cortisol levels and Hamilton Depression Rating Scale (HAMD) scores were measured at baseline, day 5, and day 21.
Main Results:
- Six out of ten patients showed significant improvement in depressive symptoms.
- Two patients exhibited a minimal treatment response.
- A positive clinical response correlated with higher baseline serum cortisol levels.
Conclusions:
- Dexamethasone may be a viable adjunct treatment for patients with major depression resistant to standard antidepressants.
- Elevated baseline cortisol may predict a favorable response to dexamethasone in this patient group.